Share New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026

PRNewsWire · BIIB · November 16, 2026

New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026

Stocks To Buy Now app

Get the app for more

Explore stock news, insights and company research.

Get the app →
Source: PRNewsWire ↗